BI-3820768 in germ cell cancers: NCT07306559 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 18 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1
Clinical phase
Recruiting
Recruitment status
187
Planned enrollment
2029-09-07
Primary-completion proxy
Executive view
NCT07306559 evaluates BI-3820768 in germ cell cancers. The disclosed sponsor is Boehringer Ingelheim GmbH, the design is Interventional, and the geographic footprint is Belgium, United States, Japan, France, Germany, Spain. The first listed primary endpoint is Occurrence of treatment-emergent AEs, assessed over up to 3 years..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07306559 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider germ cell cancers landscape. Drug & Asset MCP drug_fetch was queried for BI-3820768, while Company & Deal Intelligence MCP organization_fetch was queried for Boehringer Ingelheim GmbH.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07306559 | BI-3820768 | Phase 1 / Recruiting | Boehringer Ingelheim GmbH | Belgium, United States, Japan, France, Germany, Spain | Occurrence of treatment-emergent AEs up to 3 years. | 2029-09-07 |
| NCT07470853 | HWK-016 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles) | 2028-02-01 |
| NCT07462663 | GLP-1 agonist (Nxera Pharma) | Phase 4 / Not yet recruiting | Bellvitge University Hospital | Geography not reported | Recruitment Rate From study opening to end of recruitment, up to 36 months. | 2031-04-01 |
| NCT07453394 | Olaparib | Phase 1/2 / Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | Geography not reported | Incidence and severity of adverse events up to 2 years | 2027-04-01 |
| NCT07444814 | HWK-007 | Phase 1 / Recruiting | Whitehawk Therapeutics, Inc. | United States | Determine Maximum Tolerated Dose (MTD) From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles) | 2028-10-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07306559 is a Phase 1, recruiting study with 187 planned participants. Allocation is Non-Randomized, masking is None (Open Label), and the intervention model is Sequential Assignment.
The primary endpoint is “Occurrence of treatment-emergent AEs” over “up to 3 years..” The retrieved endpoint description is: AEs=Adverse Events.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 187 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for germ cell cancers. These records do not establish direct evidence for NCT07306559 unless the registration number matches.
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhib…
Phase 1/2; n=97; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 62 Participants ; Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 = 3 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05572684
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Phase 2; n=62; CBR = 27 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT01797523
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given…
Phase 1/2; n=19; Number of Participants With DLTs in Each Module = 0 Participants ; Number of Participants With DLTs in Each Module = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05714553
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
BI-3820768 is indexed as Antibody with target not reported biology and a global stage of Phase 1. The asset profile lists Boehringer Ingelheim GmbH as an originator or developer.
Boehringer Ingelheim GmbH is indexed in Germany with the website http://www.sds.boehringer-ingelheim.com. Boehringer Ingelheim is a group of pharmaceutical companies that focuses on prescription medicines and animal health. The record lists 155 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether BI-3820768 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07306559
Protocol source: https://clinicaltrials.gov/study/NCT07306559
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 18 September 2026.
BI-3820768 in germ cell cancers is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Occurrence of treatment-emergent AEs and 2029-09-07 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
